Literature DB >> 31810932

In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs.

Yosuke Iijima1, Kenjiro Bandow2, Motohiko Sano3, Shunsuke Hino4, Takahiro Kaneko4, Norio Horie4, Hiroshi Sakagami5.   

Abstract

BACKGROUND/AIM: The aim of the study was to evaluate the antitumor potential and combination effects of chemotherapeutic drugs.
MATERIALS AND METHODS: The cytotoxicity of 20 drip-type classical and molecular-targeted anticancer drugs was examined against 4 human oral squamous cell carcinoma cell lines and 5 human oral normal mesenchymal and epithelial cells. Cell cycle progression was monitored by a cell sorter. Combination effect was evaluated by combination index.
RESULTS: Most of the classical anticancer drugs showed much higher antitumor activity than molecular-targeted drugs, except bortezomib. Among 12 classical anticancer drugs, taxanes and gemsitabine showed the highest tumor-specificity (TS) and potency-selectivity expression (PSE) values, whereas platinum analogs showed the least TS value. Combination of two classical or a classical and a molecular-targeted drug showed mostly additive or antagonistic effect. 5-FU and cisplatin did not produce a subG1 population, but induced G2/M or G1/S arrest, regardless of the addition of cetuximab. Cetuximab, nibolumab and bortezomib showed potent keratinocyte toxicity.
CONCLUSION: The present TS monitoring system may provide useful information for building up the treatment regimens of anticancer drugs. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anticancer drugs; cell cycle analysis; combination effect; hormesis; human oral squamous cell carcinoma cells; tumor-specificity

Year:  2019        PMID: 31810932     DOI: 10.21873/anticanres.13882

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Augmentation of Neurotoxicity of Anticancer Drugs by X-Ray Irradiation.

Authors:  Giichirou Nakaya; Hiroshi Sakagami; Yukari Koga-Ogawa; Akiyoshi Shiroto; Tadamasa Nobesawa; Daisuke Ueda; Sachie Nakatani; Kenji Kobata; Yosuke Iijima; Shigenobu Tone; Angel David-Gonzalez; Rene Garcia-Contreras; Mineko Tomomura; Shinji Kito; Nobuaki Tamura; Hiroshi Takeshima
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Biological Properties of the Aggregated Form of Chitosan Magnetic Nanoparticle.

Authors:  Angel David Paulino-Gonzalez; Hiroshi Sakagami; Kenjiro Bandow; Yumiko Kanda; Yuko Nagasawa; Yasushi Hibino; Hiroshi Nakajima; Satoshi Yokose; Osamu Amano; Giichirou Nakaya; Yukari Koga-Ogawa; Akiyoshi Shiroto; Tadamasa Nobesawa; Daisuke Ueda; Sachie Nakatani; Kenji Kobata; Yosuke Iijima; Shinsuke Ifuku; Masaji Yamamoto; Rene Garcia-Contreras
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer.

Authors:  Carlos Narvaez; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

4.  Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.

Authors:  Vassiliki Mpakou; Aris Spathis; Anthi Bouhla; Efthimia Mpazani; Sotirios Papageorgiou; Konstantinos Gkontopoulos; Eirini Glezou; Thomas Thomopoulos; Periklis Foukas; Vasiliki Pappa
Journal:  Exp Ther Med       Date:  2021-01-08       Impact factor: 2.447

5.  IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.

Authors:  Meri Sieviläinen; Jordan Saavalainen; Shady Adnan-Awad; Tuula Salo; Ahmed Al-Samadi
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

6.  Dichloroacetyl Amides of 3,5-Bis(benzylidene)-4-piperidones Displaying Greater Toxicity to Neoplasms than to Non-Malignant Cells.

Authors:  Mohammad Hossain; Praveen K Roayapalley; Hiroshi Sakagami; Keitaro Satoh; Kenjiro Bandow; Umashankar Das; Jonathan R Dimmock
Journal:  Medicines (Basel)       Date:  2022-06-08

7.  Re-Evaluation of Chemotherapeutic Potential of Pyoktanin Blue.

Authors:  Hiroshi Sakagami; Toshiko Furukawa; Keitaro Satoh; Shigeru Amano; Yosuke Iijima; Takuro Koshikawa; Daisuke Asai; Kunihiko Fukuchi; Hiromu Takemura; Taisei Kanamoto; Satoshi Yokose
Journal:  Medicines (Basel)       Date:  2021-06-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.